RetinalGenix Technologies
RetinalGenix Technologies Inc. (OTC: RTGX) is a medical technology company developing a non-invasive retinal imaging diagnostic system designed to detect biomarkers of neurological and vascular diseases — including Alzheimer's disease, diabetic retinopathy, and cardiovascular disease risk factors — through high-resolution imaging of the retina, the light-sensitive layer at the back of the eye whose vascular and neural structures are uniquely accessible to non-invasive imaging and have been shown to reflect systemic health conditions throughout the body. According to its website at retinalgenix.com, the company's retinal imaging platform aims to provide clinicians and healthcare systems with a rapid, accessible, and non-invasive screening tool that can identify individuals at elevated risk for significant neurological and vascular conditions — enabling earlier intervention and more proactive management of conditions that are currently diagnosed at more advanced stages when treatment options are more limited.
RetinalGenix Technologies' diagnostic platform, described at retinalgenix.com, is built on the scientific evidence demonstrating correlations between retinal vascular and neurological characteristics — including retinal vessel caliber, vascular network complexity, and amyloid beta deposits visible in the retina — and systemic conditions including Alzheimer's disease, diabetic complications, hypertension, and cardiovascular disease. The company's proprietary imaging software applies artificial intelligence and image analysis algorithms to high-resolution retinal images to detect and quantify these retinal biomarkers, potentially enabling population-level screening for diseases that currently require expensive, complex diagnostic procedures. The retina's unique optical accessibility — the only part of the central nervous system directly visible through a non-invasive optical instrument — makes retinal imaging an attractive platform for systemic disease biomarker detection.
RetinalGenix Technologies is a development-stage company pursuing the clinical validation and regulatory clearance of its retinal imaging diagnostic platform for specified disease detection applications. According to retinalgenix.com, the company's development strategy involves conducting the clinical studies required to establish the sensitivity, specificity, and clinical utility of its retinal biomarker detection capabilities, building the evidence base required to support FDA clearance for screening or diagnostic applications and commercial adoption by healthcare providers and health systems. RetinalGenix Technologies' combination of retinal imaging diagnostic platform, neurological and vascular disease biomarker detection focus, AI-powered image analysis technology, OTC-listed development company structure, and mission to enable earlier disease detection through accessible retinal screening reflects its participation in the emerging field of retinal biomarker diagnostics.